Remes-Troche JM, Carmona-Sánchez R, Soto PJC, González MM, Icaza CME, Torres BG, Sánchez MA, Valdovinos DMA

Language: Spanish
References: 26
Page: 276-283
PDF size: 64.66 Kb.

ABSTRACT

Background: Proton pump inhibitor test (PPIt) has been shown adequate diagnostic usefulness and cost-effectiveness in the evaluation of patients with gastroesophageal reflux disease (GERD). However, comparative studies of PPIt with 24 hr esophageal pH-metry (24-pH) in non erosive GERD (NERD) are scarce and the utility of rabeprazole as a PPIt has not been evaluated. Objective: To investigate the diagnostic utility of rabeprazole test in patients with NERD. Material and methods: An open label trial was performed, and NERD patients with heartburn at least 3 times per week were included. Symptomatic evaluation before, during and after rabeprazole 20 mg bid for 7 days was performed. All patients underwent 24-pH before treatment with rabeprazole. Patients were classified in three groups: 1) abnormal pH, 2) normal pH and symptom index (SI) positive, and 3) normal pH and SI negative. A positive rabrepazole test was considered when symptoms improvement was higher than 50% at the end of the test. Sensitivity, specificity, negative predictive value, positive predictive value and positive likelihood ratio were calculated considering the 24-pH as gold standard. Results: Sixty four patients, 47 (72%) female were studied. Forty four percent of the patients had normal pH, 29% with SI positive and 71% with SI negative. Sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio were 82%, 47%, 78%, 52% and 1.406 respectively. No adverse events were reported. Conclusion: PPI test with rabeprazole 20 mg bid for 7 days is a simple and useful test in the diagnostic approach of patients with NERD.

REFERENCES

1. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997; 112: 1448-56.

2. A Gallup Organization National Survey. Heartburn Across America. Princeton, NJ. Gallup 1988.

3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-6.

4. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antiacis tablets? Am J Gastroenterol 1983; 78: 257-60.

5. Sandler RS, Everhart JE, Dnonowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-11.

6. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.

7. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001; 96(2): 303-14.

8. DeMeester TR, Wang C-I, Wernly JA, et al. Technique, indications and clinical use of 24-hour esophageal pH monitoring. J Thorac Cardiovasc Surg 1980; 79: 656-70.

9. Drossman DA, Corazziari R, Talley NJ, et al, and the Rome II Multinational Working Teams. Rome II. The functional esophageal disorders. In: Drossman DA (ed.). Rome II, 2nd ed. Lawrence: Allen Press, 2000.

10. Lundell L, Backman L, Ekström P, et al. Omeprazole or high dose of ranitidine in the treatment of patients with reflux esophagitis not responding to standar doses of H2-receptor antagonist. Aliment Pharmacol Ther 1990: 4: 145-55.

11. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.

12. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assesment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 2161-68.

13. Neville PM, Moayyedi P, Edwards A. Response to pantoprazole is an effective diagnostic test for gastroesophageal reflux disease: results of a randomized double-blind placebo-controlled pilot study (abstract). Gastroenterology 1998; 114 (Suppl.): A242

14. Brun J, Sornrgard H. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastroesophageal reflux disease (GERD) . Swedish multi-centre group in a primary health care. Fam Pract 2000; 17: 401-4.

15. Numans ME, Lau J, de Wit NJ. Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. Ann Intern Med 2004; 140: 518-27.

16. Weiner GJ, Morgan TM, Cooper JB, et al. Ambulatory 24-hour esophageal pH monitoring, reproducibility and variability of pH parameters. Dig Dis Sci 1988; 33: 1127-33.

17. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.

18. Juul-Hansen P, Rydning A, Jacobsen CD, Hansen T. High-dose proton pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol 2001; 36: 806-10.

19. Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 59-66.

20. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000; 14: 389-96.

21. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. Oneweek omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33: 15-20.

22. Delchier JC, Cohen G, Humpphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastroesophageal reflux disease. Scand J Gastroenterol 2000; 35: 1245-50.

23. Holtmann G, Bytzer P, Metz M, et al. A randomized, double-blinded, comparative study of Standard-dose rabeprazole and high-dose omeprazole in gastro-esophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-85.

24. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 2004; 64: 277-95.

25. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-9.

26. Remes-Troche JM, Gómez-Escudero O, Ruíz JC, Schmulson M, Valdovinos-Díaz M. Percepción de síntomas con descensos mínimos en el pH esofágico en pacientes con ERGE erosiva y no erosiva. Rev Gastroenterol Mex 2004; 69: 30-5.